Hollingsworth Jane H
Known title: DirectorCIK: 0001297141
Associated companies
Transaction History
| CRVO | ▲ Buy | Option Exercise | 122 | — | 8/31/2023 | View on chart |
| CRVO | ▼ Sell | Other | 45 | — | 8/31/2023 | View on chart |
| CRVO | ▲ Buy | Option Exercise | 183 | — | 5/31/2023 | View on chart |
| CRVO | ▼ Sell | Other | 68 | — | 5/31/2023 | View on chart |
| CRVO | ▼ Sell | Other | 68 | — | 2/28/2023 | View on chart |
| CRVO | ▲ Buy | Option Exercise | 183 | — | 2/28/2023 | View on chart |
| CRVO | ▲ Buy | Option Exercise | 183 | — | 11/30/2022 | View on chart |
| CRVO | ▼ Sell | Other | 68 | — | 11/30/2022 | View on chart |
| CRVO | ▲ Buy | Option Exercise | 183 | — | 8/31/2022 | View on chart |
| CRVO | ▼ Sell | Other | 67 | — | 8/31/2022 | View on chart |
| CRVO | ▲ Buy | Option Exercise | 183 | — | 5/31/2022 | View on chart |
| CRVO | ▼ Sell | Other | 67 | — | 5/31/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
CervoMed Reports PK Data and FDA Removal of Exposure Limit
CervoMed announced pharmacokinetic results for its new oral tablet formulation of neflamapimod. The company also secured the FDA's removal of a drug exposure limit, a regulatory update that may affect future development steps. These developments provide context for the stock's recent price movement within its 52-week range.
CervoMed Reports PK Data and FDA Removal of Exposure Limit. CervoMed announced pharmacokinetic results for its new oral tablet formulation of neflamapimod. The company also secured the FDA's removal of a drug exposure limit, a regulatory update that may affect future development steps. These developments provide context for the stock's recent price movement within its 52-week range.